The mTOR pathway is one of the pathways that show consistent aberrant activation in ccRCC, and interestingly, we found that during enrichment, TCIRG1 showed a significant correlation, which may be another potential mechanism for predicting progression and poor prognosis in patients with ccRCC. Here, MTOR is linked to nonpapillary renal cell carcinoma.